Nicola P. Klein, MD, PhD

Director
Kaiser Permanente Vaccine Study Center

Disclosure: GSK group of companies (Research Grant or Support)Merck (Grant/Research Support)Pfizer (Grant/Research Support)Protein Science (now SP) (Grant/Research Support)Sanofi Pasteur (Grant/Research Support)

Nicola Klein, MD, PhD is a board-certified Pediatrician, Director of the Kaiser Permanente Vaccine Study Center, Research Scientist III at the Kaiser Permanente Northern California Division of Research, and a Professor in the Department of Health Systems Science at the Kaiser Permanente Bernard J. Tyson School of Medicine. Her research has focused on vaccine safety and effectiveness, genetics of vaccine responses, vaccine safety among special populations and the epidemiology of vaccine preventable diseases. She is the principal investigator (PI) for the CDC-sponsored Vaccine Safety Datalink (VSD) project and the Clinical Immunization Safety Assessment Network. She recently led the VSD COVID-19 vaccines Rapid Cycle Analysis (RCA), which monitors the safety of vaccines in near real-time and is the CDC’s primary active surveillance safety monitoring system for COVID-19 vaccines. She is PI for both industry and federally sponsored Phase 2 and 3 vaccine clinical trials, including mRNA COVID-19 vaccines. She had led observational studies investigating the effectiveness of many vaccines, including pivotal studies describing waning effectiveness of acellular pertussis vaccines, the effectiveness of influenza, live-attenuated zoster, human papilloma virus, pneumococcal conjugate vaccines, COVID-19 and recombinant shingles vaccines, as well as comparative effectiveness of different influenza vaccines. She recently served on the Western States Scientific Safety Review Workgroup for COVID-19 vaccines and is currently a member of both the National Vaccine Advisory Committee (NVAC) Vaccine Safety Subcommittee and the National Academy of Medicine Board of Population Health.